Page last updated: 2024-08-16

thalidomide and cenersen

thalidomide has been researched along with cenersen in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Al Ali, NH; Basiorka, A; Boultwood, J; Caceres, G; Daugherty, FJ; Fulp, WJ; Johnson, J; Komrokji, RS; Lee, JH; List, AF; Littleton, N; Liu, K; McGraw, K; Pellagatti, A; Smith, LJ; Sokol, L; Wei, S; Wells, RA; Yip, BH; Zhang, L; Zhang, LM	1

Other Studies

1 other study(ies) available for thalidomide and cenersen

Article	Year
TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proceedings of the National Academy of Sciences of the United States of America, 2013, Oct-01, Volume: 110, Issue:40 Topics: Base Sequence; Dexamethasone; Drug Resistance; Erythroid Precursor Cells; Erythropoiesis; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lenalidomide; Molecular Sequence Data; Myelodysplastic Syndromes; Oligonucleotides; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Statistics, Nonparametric; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53	2013

Article

Year

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.

Proceedings of the National Academy of Sciences of the United States of America, 2013, Oct-01, Volume: 110, Issue:40

Topics: Base Sequence; Dexamethasone; Drug Resistance; Erythroid Precursor Cells; Erythropoiesis; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lenalidomide; Molecular Sequence Data; Myelodysplastic Syndromes; Oligonucleotides; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA; Statistics, Nonparametric; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53

2013